Decipher Prostate – pro
Decipher’s genomic test, performed on tumor tissue, matches selection and intensity of treatment with the metastatic potential of the tumor by providing quantitative estimate of risk of metastatic disease and dividing the cancers into high-risk, intermediate and low risk. Decipher has been validated in 40 studies across 29,876 patients for metastasis, prostate cancer-specific mortality, and overall survival. The National Comprehensive Cancer Network (NCCN) 2020 Clinical Practice Guidelines on Prostate Cancer state the following regarding molecular assays: “Men with low or favorable intermediate risk disease may consider the use of the
following tumor-based molecular assays: Decipher, Oncotype DX Prostate, Prolaris, Promark. Retrospective studies have shown that molecular assays performed on prostate biopsy or radical prostatectomy specimens provide prognostic information independent of NCCN risk groups.”
DeSanda MG, Cadeddu JA, Kirkby E, et al. Clinical localized prostate cancer: AUA/ASTRO/SUO guideline. part I: risk stratification, shared decision making, and care options. Journal of Urology. March 2018; 199:683-690.
American Association of Clinical Urologists, Inc. (AACU) website. Position statement: genomic testing in prostate cancer. Available at:
https://aacuweb.org/docs/position-statements/ps_genomic-testing-in-prostatecancer.aspx
NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer. V3.2018.
Available at: https://www.nccn.org/professionals/physician_gls/pdf/prostate_blocks.pdf